首页|G. d'Annunzio University Reports Findings in Bladder Cancer (Time to progression is the main predictor of survival in patients with highrisk nonmuscle invasive bladder cancer: Results from a machine learning-based analysis of a large ...)
G. d'Annunzio University Reports Findings in Bladder Cancer (Time to progression is the main predictor of survival in patients with highrisk nonmuscle invasive bladder cancer: Results from a machine learning-based analysis of a large ...)
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NETL
NSTL
New research on Oncology - Bladder Cancer is the subject of a report. According to news reporting out of Chieti, Italy, by NewsRx editors, research stated, "In patients affected by high-risk nonmuscle invasive bladder cancer (HR-NMIBC) progression to muscle invasive status is considered as the main indicator of local treatment failure. We aimed to investigate the effect of progression and time to progression on overall survival (OS) and to investigate their validity as surrogate endpoints." Our news journalists obtained a quote from the research from G. d'Annunzio University, "A total of 1,510 patients from 18 different institutions treated for T1 high grade NMIBC, followed by a secondary transurethral resection and BCG intravesical instillation. We relied on random survival forest (RSF) to rank covariates based on OS prediction. Cox's regression models were used to quantify the effect of covariates on mortality. During a median follow-up of 49.0 months, 485 (32.1%) patients progressed to MIBC, while 163 (10.8%) patients died. The median time to progression was 82 (95%CI: 78.0-93.0) months. In RSF time-toprogression and age were the most predictive covariates of OS. The survival tree defined 5 groups of risk. In multivariable Cox's regression models accounting for progression status as time-dependent covariate, shorter time to progression (as continuous covariate) was associated with longer OS (HR: 9.0, 95%CI: 3.0-6.7; P＜0.001). Virtually same results after time to progression stratification (time to progression 10.5 months as reference). Time to progression is the main predictor of OS in patients with high risk NMIBC treated with BCG and might be considered a coprimary endpoint."
ChietiItalyEuropeBladder CancerCancerCyborgsEmerging TechnologiesHealth and MedicineMachine LearningOncology
NETL
NSTL
